AxoGen (AXGN) 47th Annual Raymond James Institutional Investor Conference summary

Mission and market focus

• Aims to make restoration of peripheral nerve function a standard of care, addressing trauma and iatrogenic injuries.

• Strategic focus on extremities, breast reconstruction, oral maxillofacial/head and neck, and developing prostate care.

• Current growth projections (15–20% annually over 3–5 years) are based on the first three markets, with prostate care as a future addition.

• Barriers include lack of awareness, incomplete care guidelines, and gaps in payer coverage.

• Commercial expansion and surgeon training are ongoing priorities to increase adoption.

Product portfolio and regulatory milestones

• AVANCE Nerve Graft is the first approved biologic therapeutic for nerve discontinuities, driving about 60% of revenue.

• Recent FDA Biologics License Application (BLA) approval for AVANCE validates its safety and efficacy, supporting payer and customer engagement.

• BLA approval enables new clinical studies, streamlines manufacturing under a single quality system, and is expected to enhance gross margins.

• BLA status helps address payer concerns about the product being experimental, aiding in achieving broader coverage.

Financial performance and outlook

• Guidance for 2024: at least 18% revenue growth to $266 million, gross margin of 74–76%, and net free cash flow positivity.

• Recently raised $142 million, using $68 million to pay off high-interest debt, improving balance sheet and cash flow.

• Remaining funds will support opportunistic investments, innovation, and reduce dilution from stock-based compensation.

• Long-term gross margin target remains above 75%, with further details expected in late 2026.